Targeting C-reactive protein for the treatment of cardiovascular disease.
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Complement-mediated inflammation exacerbates the tissue injury of ischaemic necrosis in heart attacks and strokes, the most common causes of death in developed countries. Large infarct size increases immediate morbidity and mortality and, in survivors of the acute event, larger non-functional scars adversely affect long-term prognosis. There is thus an important unmet medical need for new cardioprotective and neuroprotective treatments. We have previously shown that human C-reactive protein (CRP), the classical acute-phase protein that binds to ligands exposed in damaged tissue and then activates complement, increases myocardial and cerebral infarct size in rats subjected to coronary or cerebral artery ligation, respectively. Rat CRP does not activate rat complement, whereas human CRP activates both rat and human complement. Administration of human CRP to rats is thus an excellent model for the actions of endogenous human CRP. Here we report the design, synthesis and efficacy of 1,6-bis(phosphocholine)-hexane as a specific small-molecule inhibitor of CRP. Five molecules of this palindromic compound are bound by two pentameric CRP molecules, crosslinking and occluding the ligand-binding B-face of CRP and blocking its functions. Administration of 1,6-bis(phosphocholine)-hexane to rats undergoing acute myocardial infarction abrogated the increase in infarct size and cardiac dysfunction produced by injection of human CRP. Therapeutic inhibition of CRP is thus a promising new approach to cardioprotection in acute myocardial infarction, and may also provide neuroprotection in stroke. Potential wider applications include other inflammatory, infective and tissue-damaging conditions characterized by increased CRP production, in which binding of CRP to exposed ligands in damaged cells may lead to complement-mediated exacerbation of tissue injury.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Heuristics may lead to bias or predictable and systematic cognitive errors, as described in Table 2.16,35”
From Artificial Intelligence and Surgical Decision-making. (2020) · cites this paper as [54]
Citations
Cites
PROCHECK: a program to check the stereochemical quality of protein structures
Laskowski, R. A., MacArthur, M. W., Moss, D. S., & Thornton, J. M. (1993) · Journal of Applied Crystallography · doi:10.1107/s0021889892009944 · Cited by 24,581
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination
Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., et al. (1998) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444998003254 · Cited by 15,715
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,742
MOLREP: an Automated Program for Molecular Replacement
Vagin, A., & Teplyakov, A. (1997) · Journal of Applied Crystallography · doi:10.1107/s0021889897006766 · Cited by 4,714
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18921 · Cited by 3,503
Self-citationWHAT IF: A molecular modeling and drug design program
Vriend, G. (1990) · Journal of Molecular Graphics · doi:10.1016/0263-7855(90)80070-v · Cited by 3,469
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318921 · Cited by 3,436
Self-citationThe integration of macromolecular diffraction data
Leslie, A. G. W. (2006) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444905039107 · Cited by 1,341
The physiological structure of human C-reactive protein and its complex with phosphocholine
Thompson, D., Pepys, M. B., & Wood, S. P. (1999) · Structure · doi:10.1016/s0969-2126(99)80023-9 · Cited by 818
Self-citation
Cited by
Role of C-Reactive Protein at Sites of Inflammation and Infection
Sproston, N. R., & Ashworth, J. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00754 · Cited by 3,029
“Thus, in addition to therapeutic strategies to inhibit CRP activity (51), more targeted therapies have been proposed for the treatment of CRP-mediated pathologies, including inhibiting mCRP activity (52) or preventing the dissociation of nCRP into mCRP (53).”
BackgroundMechanisms of Diabetic Complications
Forbes, J. M., & Cooper, M. E. (2013) · Physiological Reviews · doi:10.1152/physrev.00045.2011 · Cited by 2,890
“CVD accounts for more than half of the mortality seen in the diabetic population (228, 319), and diabetes equates to an approximately threefold increased risk of myocardial infarction compared with the general population (155).”
BackgroundInfluentialColchicine in Patients with Chronic Coronary Disease
Nidorf, S. M., Fiolet, A. T. L., Mosterd, A., Eikelboom, J. W., Schut, A., Opstal, T. S. J., The, S. H. K., Xu, X.-F., Ireland, M. A., Lenderink, T., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2021372 · Cited by 2,299
Systemic manifestations and comorbidities of COPD
Barnes, P. J., & Celli, B. R. (2009) · European Respiratory Journal · doi:10.1183/09031936.00128008 · Cited by 1,820
Regulation of the Inflammatory Response in Cardiac Repair
Frangogiannis, N. G. (2012) · Circulation Research · doi:10.1161/circresaha.111.243162 · Cited by 1,194
Vaisar, T., Pennathur, S., Green, P. S., Gharib, S. A., Hoofnagle, A. N., Cheung, M. C., Byun, J., Vuletic, S., Kassim, S., Singh, P., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci26206 · Cited by 942
Pathophysiology of Heart Failure
Tanai, E., & Frantz, S. (2015) · Comprehensive Physiology · doi:10.1002/cphy.c140055 · Cited by 552
“Administration of a potent CRP inhibitor, 1,6-bis-(phosphocholine)-hexane, to rats after acute myocardial infarction increases infarct size and cardiac dysfunction, induced by human CRP (98).”
The immune system and cardiac repair
FRANGOGIANNIS, N. (2008) · Pharmacological Research · doi:10.1016/j.phrs.2008.06.007 · Cited by 641
Artificial Intelligence and Surgical Decision-making.
Loftus, T. J., Tighe, P. J., Filiberto, A. C., Efron, P. A., Brakenridge, S. C., Mohr, A. M., Rashidi, P., Upchurch, G. R., & Bihorac, A. (2020) · JAMA Surgery · doi:10.1001/jamasurg.2019.4917 · Cited by 650
“34,43,56 Parametric regression equations also fail to represent the complex, nonlinear associations among input variables, further limiting the accuracy of traditional multivariable regression models.”
BackgroundC Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC) (2011) · BMJ · doi:10.1136/bmj.d548 · Cited by 642
C-Reactive Protein and the Prediction of Cardiovascular Events Among Those at Intermediate Risk
Ridker, P. M. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.052 · Cited by 623
“One such agent has been described and, at least in animal models, has shown promise (98).”
Zouggari, Y., Ait-Oufella, H., Bonnin, P., Simon, T., Sage, A. P., Guérin, C., Vilar, J., Caligiuri, G., Tsiantoulas, D., Laurans, L., et al. (2013) · Nature Medicine · doi:10.1038/nm.3284 · Cited by 559
“C-reactive protein, a short pentraxin acute-phase protein, also binds damaged tissue and activates complement, leading to aggravation of tissue injury in the setting of acute myocardial infarction 13 .”
BackgroundFruit and vegetable intakes, C-reactive protein, and the metabolic syndrome
Esmaillzadeh, A., Kimiagar, M., Mehrabi, Y., Azadbakht, L., Hu, F. B., & Willett, W. C. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/84.6.1489 · Cited by 524
“As recently reported, CRP may directly affect cardiovascular disease through a complementmediated process (24).”
BackgroundObesity and Obesity-Initiated Metabolic Syndrome: Mechanistic Links to Chronic Kidney Disease
Wahba, I. M., & Mak, R. H. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04071206 · Cited by 513
Cancer cachexia, mechanism and treatment
Aoyagi, T., Terracina, K. P., Raza, A., Matsubara, H., & Takabe, K. (2015) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v7.i4.17 · Cited by 434
The disconnect between animal models of sepsis and human sepsis
Rittirsch, D., Hoesel, L. M., & Ward, P. A. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0806542 · Cited by 406
“For instance, human C-reactive protein (CRP), an acute-phase protein and popular marker for inflammation, is known to be an activator of the complement system in humans, but in contrast, rat CRP does not influence the complement system [74, 75].”
BackgroundAssessment of Plasma C-Reactive Protein as a Biomarker of Posttraumatic Stress Disorder Risk
Eraly, S. A., Nievergelt, C. M., Maihofer, A. X., Barkauskas, D. A., Biswas, N., Agorastos, A., O’Connor, D. T., & Baker, D. G. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.4374 · Cited by 386
Sabatine, M. S., Morrow, D. A., Jablonski, K. A., Rice, M. M., Warnica, J. W., Domanski, M. J., Hsia, J., Gersh, B. J., Rifai, N., Ridker, P. M., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.649939 · Cited by 385
C‐reactive protein and coronary heart disease: a critical review
Casas, J. P., Shah, T., Hingorani, A. D., Danesh, J., & Pepys, M. B. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.02015.x · Cited by 366
Self-citationRidker, P. M., Pare, G., Parker, A., Zee, R. Y. L., Danik, J. S., Buring, J. E., Kwiatkowski, D., Cook, N. R., Miletich, J. P., & Chasman, D. I. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.03.015 · Cited by 343
“Moreover, direct CRP inhibitors with apparent vascular-protective effects have recently been described.(31) However, it remains controversial as to whether CRP itself is a target for therapy, and other data (albeit with limited power to define an informative null result) have not linked CRP polymorphism to incident ev…”
BackgroundCardioprotective Function of the Long Pentraxin PTX3 in Acute Myocardial Infarction
Salio, M., Chimenti, S., De Angelis, N., Molla, F., Maina, V., Nebuloni, M., Pasqualini, F., Latini, R., Garlanda, C., & Mantovani, A. (2008) · Circulation · doi:10.1161/circulationaha.107.749234 · Cited by 327
C-reactive protein and inflammation: conformational changes affect function
Wu, Y., Potempa, L. A., El Kebir, D., & Filep, J. G. (2015) · Biological Chemistry · doi:10.1515/hsz-2015-0149 · Cited by 285
Inflammation, C‐Reactive Protein, and Atherothrombosis
Ridker, P. M., & Silvertown, J. D. (2008) · Journal of Periodontology · doi:10.1902/jop.2008.080249 · Cited by 279
Anti‐inflammatory therapies in myocardial infarction: failures, hopes and challenges
Huang, S., & Frangogiannis, N. G. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14155 · Cited by 282
“(Morton et al., 2015) RCT: CANTOS 10 061 Canakinumab (anti-IL-1β) at three different doses: 50, 150 and 300 mg In patients with previous MI and an hs-CRP level ≥ 2 mg·L 1, canakinumab (150 mg) significantly reduced hs-CRP, (Ridker et al., 2017) continues British Journal of Pharmacology (2018) 175 1377–1400 1389 Table…”
BackgroundInfluentialTherapeutic targets in rheumatoid arthritis: the interleukin-6 receptor
Dayer, J.-M., & Choy, E. (2010) · Rheumatology · doi:10.1093/rheumatology/kep329 · Cited by 267
Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease
(2010) · National Academies Press eBooks · doi:10.17226/12869 · Cited by 276
RIDKER, P. M. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03404.x · Cited by 270
Lange, L. A., Carlson, C. S., Hindorff, L. A., Lange, E. M., Walston, J., Durda, J. P., Cushman, M., Bis, J. C., Zeng, D., Lin, D., et al. (2006) · JAMA · doi:10.1001/jama.296.22.2703 · Cited by 266
Inflammation and ischaemic stroke
Muir, K. W., Tyrrell, P., Sattar, N., & Warburton, E. (2007) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32813ba151 · Cited by 264
Applications of ESI-MS in drug discovery: interrogation of noncovalent complexes
Hofstadler, S. A., & Sannes-Lowery, K. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2083 · Cited by 250
Hage, F. G., & Szalai, A. J. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.06.012 · Cited by 241
Cancer cachexia: impact, mechanisms and emerging treatments
Vaughan, V. C., Martin, P., & Lewandowski, P. A. (2013) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-012-0087-1 · Cited by 233
“CRP is considered an accurate measure of proinflammatory cytokine activity [85] that has been implicated in muscle wasting by its binding to exposed ligands in damaged cells and has been shown to aggravate tissue damage in ischemia–reperfusion injury [86].”
BackgroundThe Evolving Role of C-Reactive Protein in Atherothrombosis
Devaraj, S., Singh, U., & Jialal, I. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.108886 · Cited by 233
C-reactive protein is a mediator of cardiovascular disease
Bisoendial, R. J., Boekholdt, S. M., Vergeer, M., Stroes, E. S. G., & Kastelein, J. J. P. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq238 · Cited by 232
Thiele, J. R., Habersberger, J., Braig, D., Schmidt, Y., Goerendt, K., Maurer, V., Bannasch, H., Scheichl, A., Woollard, K. J., von Dobschütz, E., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.007124 · Cited by 214
“Previous animal models of myocardial infarction have found that CRP directly contributes to myocardial cell death and necrosis.(5,7) This finding is consistent with observational studies after myocardial infarction in humans, which have found that the peak serum (p)CRP level correlates with adverse clinical outcomes.”
BackgroundResultInfluentialObesity: Genes, brain, gut, and environment
Das, U. N. (2010) · Nutrition · doi:10.1016/j.nut.2009.09.020 · Cited by 206
“Human CRP activated complement and 1,6-bis(phosphocholine)-hexane, a specific small molecule inhibitor of CRP, abrogated the increase in infarct size and cardiac dysfunction produced by injection of human CRP in rats [83].”
BackgroundTransitional changes in the CRP structure lead to the exposure of proinflammatory binding sites
Braig, D., Nero, T. L., Koch, H.-G., Kaiser, B., Wang, X., Thiele, J. R., Morton, C. J., Zeller, J., Kiefer, J., Potempa, L. A., et al. (2017) · Nature Communications · doi:10.1038/ncomms14188 · Cited by 205
“The phosphocholine moieties of the inhibitor 1,6-bis-PC have been shown to interact in a likewise manner 20 .”
InfluentialRidker, P. M. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.119214 · Cited by 206
“... inhibition of fibrinolysis, promotion of tissue factor, reduction of endothelial nitric oxide, increases in cellular adhesion, and induction of gluconeogenesis andleptinresistance(82–89).However,asMarkPepys has pointed out, no deficiency state in humans is known, data on lack of function do not currently exist, an…”
BackgroundC-reactive protein: a target for therapy to reduce inflammation
Rizo-Téllez, S. A., Sekheri, M., & Filep, J. G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1237729 · Cited by 182
“(1,6-bis (phosphocholine) -hexane) Rat Acute myocardial infarction ↓ mortality ↓ infarct size ↓ cardiac dysfunction (72)”
BackgroundMethodInfluentialJi, S., Wu, Y., Zhu, L., Potempa, L. A., Sheng, F., Lu, W., & Zhao, J. (2007) · The FASEB Journal · doi:10.1096/fj.06-6722com · Cited by 198
“necrotic cell debris (38), enhance uptake of atherogenic LDL derivatives (40) and apoptotic macrophages induced by cholesterol-loading in atheroma (41), and promote complement-mediated injury during heart attack (33).”
BackgroundInfluentialAssociation of TNF-α with insulin resistance in type 2 diabetes mellitus
Swaroop, J. J., Rajarajeswari, D., & Naidu, J. N. (2012) · Indian Journal of Medical Research · doi:10.4103/0971-5916.93435 · Cited by 189
Autonomic Neuropathy in Diabetes Mellitus
Verrotti, A., Prezioso, G., Scattoni, R., & Chiarelli, F. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00205 · Cited by 187
Prognostic Value of High-Sensitivity C-Reactive Protein in Heart Failure: A Systematic Review
Araújo, J. P., Lourenço, P., Azevedo, A., Friões, F., Rocha-Gonçalves, F., Ferreira, A., & Bettencourt, P. (2009) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2008.10.030 · Cited by 173
Human C-reactive protein induces endothelial dysfunction and uncoupling of eNOS in vivo
Hein, T. W., Singh, U., Vasquez-Vivar, J., Devaraj, S., Kuo, L., & Jialal, I. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.02.002 · Cited by 176
Insulin as an Anti-Inflammatory and Antiatherogenic Modulator
Dandona, P., Chaudhuri, A., Ghanim, H., & Mohanty, P. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.038 · Cited by 169
The HDL proteome: a marker–and perhaps mediator–of coronary artery disease
Heinecke, J. W. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800097-jlr200 · Cited by 169
“Complement activation helps mediate tissue damage in animal models of acute myocardial infarction (23).”
Backgroundthe PAIS investigators, Hertog, H. M., Rossum, J. A., Worp, H. B., Gemert, H. M. A., Jonge, R., Koudstaal, P. J., & Dippel, D. W. J. (2009) · Journal of Neurology · doi:10.1007/s00415-009-5228-x · Cited by 163
“Moreover, in animal models of focal cerebral ischemia, CRP increased secondary brain damage through activation of the complement system [13, 22].”
BackgroundMcFadyen, J. D., Kiefer, J., Braig, D., Loseff-Silver, J., Potempa, L. A., Eisenhardt, S. U., & Peter, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01351 · Cited by 152
“Therefore, while the administration of exogenous human CRP to rodents has afforded essential insights regarding CRP biology, it does not allow for in vivo mechanistic studies of CRP in chronic inflammatory conditions such as IRI, transplant rejection, atherosclerosis, or AMD.”
BackgroundInfluentialInflammation in Human Heart Failure: Major Mediators and Therapeutic Targets
Reina‐Couto, M., Pereira‐Terra, P., Quelhas‐Santos, J., Silva-Pereira, C., Albino‐Teixeira, A., & Sousa, T. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.746494 · Cited by 180
Brunner, E. J., Kivimäki, M., Witte, D. R., Lawlor, D. A., Smith, G. D., Cooper, J. A., Miller, M., Lowe, G. D. O., Rumley, A., Casas, J. P., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050155 · Cited by 163
“Preventing or delaying onset of diabetes and its complications is an important therapeutic aim, and there is interest in inflammatory effectors including CRP as drug targets [11,12].”
BackgroundHemingway, H., Philipson, P., Chen, R., Fitzpatrick, N. K., Damant, J., Shipley, M., Abrams, K. R., Moreno, S., McAllister, K. S. L., Palmer, S., et al. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000286 · Cited by 161
“and randomisation to specific biomarker lowering agents”
Complement-Mediated Ischemia-Reperfusion Injury: Lessons Learned From Animal and Clinical Studies
Diepenhorst, G. M. P., van Gulik, T. M., & Hack, C. E. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e3181a38f45 · Cited by 178
“More recently, a specific small-molecule inhibitor of CRP (1,6-bis phosphocholine -hexane) was developed, which was able to abrogate this CRP-induced increase in infarct size and its resulting cardiac dysfunction.(65,79) Hence, complement activation by CRP seems to be an important mediator in myocardial I/R and extrap…”
BackgroundDevaraj, S., & Jialal, I. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.225508 · Cited by 156
Akhmedov, A. T., Sawamura, T., Chen, C., Kraler, S. C., Vdovenko, D., & Lüscher, T. F. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa770 · Cited by 170
Owens, C. D., Gasper, W. J., Rahman, A. S., & Conte, M. S. (2015) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2013.08.019 · Cited by 144
“Pentraxins can be thought of as primitive antibodies that circulate at normally low levels and police for a limited repertoire of damage patterns commonly seen in invading microbes or damaged cell surfaces.(79) In this sense, they can be thought of as the humoral arm of the innate immune system.”
BackgroundThe connection between C‐reactive protein and atherosclerosis
Singh, S. K., Suresh, M. V., Voleti, B., & Agrawal, A. C. (2008) · Annals of Medicine · doi:10.1080/07853890701749225 · Cited by 160
“A PCh-based compound was recently reported to inhibit the deposition of human CRP at the rat myocardial infarcts and inhibit the subsequent activation of the rat complement (7).”
BackgroundHamilton, F., Thomas, M., Arnold, D., Palmer, T., Moran, E., Mentzer, A. J., Maskell, N. A., Baillie, J. K., Summers, C., Hingorani, A. D., et al. (2023) · PLoS Medicine · doi:10.1371/journal.pmed.1004174 · Cited by 157
“Given the ongoing development of therapeutics that target trans-specific IL-6 signalling and therapeutics that target CRP itself, this may represent a future avenue in sepsis therapeutics [43,44]; however, this does not alter the interpretation of the primary IL6R blockade-related finding here.”
BackgroundAfilalo, J., Majdan, A. A., & Eisenberg, M. J. (2007) · Heart · doi:10.1136/hrt.2006.112508 · Cited by 143
Label‐Free Sensing of Biomolecules with Field‐Effect Devices for Clinical Applications
Poghossian, A., & Schöning, M. J. (2014) · Electroanalysis · doi:10.1002/elan.201400073 · Cited by 142
C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling
Singh, U. S., Devaraj, S., Vasquez-Vivar, J. M., & Jialal, I. (2007) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2007.08.015 · Cited by 155
Leptin Induces C-Reactive Protein Expression in Vascular Endothelial Cells
Singh, P., Hoffmann, M., Wolk, R., Shamsuzzaman, A. S. M., & Somers, V. K. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.148353 · Cited by 139
Mechanisms of C-Reactive Protein-Induced Blood–Brain Barrier Disruption
Kuhlmann, C. R. W., Librizzi, L., Closhen, D., Pflanzner, T., Lessmann, V., Pietrzik, C. U., de Curtis, M., & Luhmann, H. J. (2009) · Stroke · doi:10.1161/strokeaha.108.535930 · Cited by 138
Pentraxins, humoral innate immunity and tissue injury
Manfredi, A. A., Rovere, P. Q., Bottazzi, B., Garlanda, C., & Mantovani, A. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.05.004 · Cited by 147
Firooz, N., Albert, D. A., Wallace, D., ISHIMORI, M. L., Berel, D., & Weisman, M. H. (2011) · Lupus · doi:10.1177/0961203310393378 · Cited by 148
The Endothelium and Inflammation
Trepels, T., Zeiher, A. M., & Fichtlscherer, S. (2006) · Endothelium · doi:10.1080/10623320601061862 · Cited by 163
Fujii, H., Li, S., Szmitko, P. E., Fedak, P. W. M., & Verma, S. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000242794.65541.02 · Cited by 144
Critical update on 2‐methacryloyloxyethyl phosphorylcholine (MPC) polymer science
Goda, T., Ishihara, K., & Miyahara, Y. (2015) · Journal of Applied Polymer Science · doi:10.1002/app.41766 · Cited by 135
Habersberger, J., Strang, F., Scheichl, A., Htun, N., Bassler, N., Merivirta, R., Diehl, P., Krippner, G. Y., Meikle, P. J., Eisenhardt, S. U., et al. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs237 · Cited by 145
“The demonstration that bisPC is capable of inhibiting mCRP formation confirms that pCRP dissociation is dependent on membrane binding, a process specifically inhibited by bisPC.(16) It also supports”
BackgroundMethodInfluentialDurst, R., Danenberg, H., Gallily, R., Mechoulam, R., Meir, K., Grad, E., Beeri, R., Pugatsch, T., Tarsish, E., & Lotan, C. (2007) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00098.2007 · Cited by 128
“Infarct size is reduced from 24% in CRP-treated rats 5 days after LAD ligation to 17% by 1,6-bis(phosphocholine)-hexane (23).”
Ridker, P. M. (2008) · Nutrition Reviews · doi:10.1111/j.1753-4887.2007.tb00372.x · Cited by 128
Sattar, N., Murray, H. M., McConnachie, A., Blauw, G. J., Bollen, E. L. E. M., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.643114 · Cited by 129
Regulation of C-reactive protein conformation in inflammation
Yao, Z., Zhang, Y., & Wu, H. (2019) · Inflammation Research · doi:10.1007/s00011-019-01269-1 · Cited by 130
How C-Reactive Protein Structural Isoforms With Distinctive Bioactivities Affect Disease Progression
Rajab, I. M., Hart, P. C., & Potempa, L. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02126 · Cited by 143
“(86) designed a small molecule bi-valent compound having phosphocholine groups on opposite ends of a linking group.”
BackgroundNew insights into mechanisms of atrial fibrillation
Aldhoon, B., Melenovský, V., Peichl, P., & Kautzner, J. (2010) · Physiological Research · doi:10.33549/physiolres.931651 · Cited by 146
Vendrame, S., Daugherty, A., Kristo, A. S., Riso, P., & Klimis‐Zacas, D. J. (2013) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2012.12.010 · Cited by 138
“CRP is a useful marker of subclinical chronic inflammation and a predictor of CVD [28], insulin resistance, diabetes mellitus as well as”
BackgroundAcute Modulation of Toll-Like Receptors by Insulin
Ghanim, H., Mohanty, P., Deopurkar, R., Ling Sia, C., Korzeniewski, K., Abuaysheh, S., Chaudhuri, A., & Dandona, P. (2008) · Diabetes Care · doi:10.2337/dc08-0561 · Cited by 123
“In this context, the ability of insulin to suppress CRP is also relevant, since CRP mediates injury during ischemia-reperfusion of the heart and synthetic small molecules (phasphotidyl choline derivatives), which bind to and block CRP action and reduce the size of myocardial injury (24).”
Anti-inflammatory effects of insulin
Dandona, P., Chaudhuri, A., Mohanty, P., & Ghanim, H. (2007) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e3281e38774 · Cited by 133
Pentraxins in the activation and regulation of innate immunity
Daigo, K., Inforzato, A., Barajon, I., Garlanda, C., Bottazzi, B., Meri, S., & Mantovani, A. (2016) · Immunological Reviews · doi:10.1111/imr.12476 · Cited by 131
Microcirculation and oxidative stress
Crimi, E., Ignarro, L. J., & Claudio Napoli, A. (2007) · Free Radical Research · doi:10.1080/10715760701732830 · Cited by 136
“[103] Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V, Hawkins PN, Myers RM, Smith MD, Polara A, Cobb AJ, Ley SV, Aquilina JA, Robinson CV,”
BackgroundC‐reactive protein collaborates with plasma lectins to boost immune response against bacteria
Ng, P. M. L., Saux, A. L., Lee, C. M., Tan, N. S., Lu, J., Thiel, S., Ho, B., & Ding, J. L. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601762 · Cited by 127
“In studies where CRP is administered (Rodriguez et al, 2005, 2006) or inhibited ( Pepys et al, 2006 ), monitoring of disease pathogenesis may include measuring the activation level of the lectin-mediated complement pathway.”
BackgroundFluorescent Gold Nanodots Based Sensor Array for Proteins Discrimination
Yuan, Z., Du, Y. P., Tseng, Y., Peng, M., Cai, N., He, Y., Chang, H., & Yeung, E. S. (2015) · Analytical Chemistry · doi:10.1021/ac5045302 · Cited by 122
Singh, U. P., Dasu, M. R. K., Yancey, P. G., Afify, A. M., Devaraj, S., & Jialal, I. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m700535-jlr200 · Cited by 120
Elahi, M. M., Flatman, S., & Matata, B. M. (2008) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e328317f38a · Cited by 125
Walkowski, B., Kleibert, M., Majka, M., & Wojciechowska, M. (2022) · Cells · doi:10.3390/cells11091553 · Cited by 117
“Importantly, apart from inflammation, CRP is also a mediator of inflammation with prothrombotic and proapoptotic properties [157,158], which further worsens the prognosis of patients.”
BackgroundCoventry, B. J., Ashdown, M. L., Quinn, M. A., Markovic, S. N., Yatomi-Clarke, S., & Robinson, A. P. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-102 · Cited by 130
One-step homogeneous C-reactive protein assay for saliva
Punyadeera, C., Dimeski, G., Kostner, K., Beyerlein, P., & Cooper-White, J. J. (2011) · Journal of Immunological Methods · doi:10.1016/j.jim.2011.07.013 · Cited by 119
Engineering Antifouling Conducting Polymers for Modern Biomedical Applications
Wu, J., Chen, J., Liu, K.-T., & Luo, S. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b04924 · Cited by 115
Persistently raised C‐reactive protein levels are associated with advanced periodontal disease
Linden, G. J., McClean, K., Young, I. S., Evans, A., & Kee, F. (2008) · Journal Of Clinical Periodontology · doi:10.1111/j.1600-051x.2008.01288.x · Cited by 118
Strengthening causal inference in cardiovascular epidemiology through Mendelian randomization
Smith, G. D., Timpson, N., & Ebrahim, S. (2008) · Annals of Medicine · doi:10.1080/07853890802010709 · Cited by 112
“Thus, whilst evidence as to the potential modulating effects of CRP after acute coronary events may be available (77), that concerning the causal role of chronic elevations of CRP on endpoint CVD risk is unclear.”
BackgroundC-reactive protein at the interface between innate immunity and inflammation
Peisajovich, A., Marnell, L., Mold, C., & Du Clos, T. W. (2008) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.4.3.379 · Cited by 105
Kramer, F., Torzewski, J., Kamenz, J., Veit, K., Hombach, V., Dedio, J., & Ivashchenko, Y. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2007.12.017 · Cited by 126
Inflammatory markers in ST-elevation acute myocardial infarction
Seropian, I. M., Sonnino, C., Tassell, B. W. V., Biasucci, L. M., & Abbate, A. (2015) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872615568965 · Cited by 114
Association of C-Reactive Protein With Cardiovascular Disease Mortality According to Diabetes Status
Kengne, A. P., Batty, G. D., Hamer, M., Stamatakis, E., & Czernichow, S. (2012) · Diabetes Care · doi:10.2337/dc11-1588 · Cited by 105
“Therefore, CRP may not be a target for CVD prevention (2,30).”
BackgroundLawlor, D. A., Harbord, R. M., Timpson, N. J., Lowe, G. D. O., Rumley, A., Gaunt, T. R., Baker, I., Yarnell, J. W. G., Kivimäki, M., Kumari, M., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003011 · Cited by 104
“Such an effect is implicated by findings from rodent models of beneficial effects of post-myocardial infarction CRP lowering,[56] but to our knowledge has not be demonstrated in humans.”
BackgroundBoncler, M. A., Wu, Y., & Watała, C. W. (2019) · Molecules · doi:10.3390/molecules24112062 · Cited by 120
“Hence, based on this animal model, 1,6-bis-PC was proposed as a promising CRP inhibitor with cardioprotective potential in acute myocardial infarction and possible neuroprotective effects in stroke [100].”
BackgroundTsai, S., Chung, K., Wu, J.-Y., Kuo, C., Lee, H., & Huang, S. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.08.022 · Cited by 111
“0 mg/l, which indicates people who are at a high risk of cardiovascular disease (Pepys et al., 2006).”
InfluentialTargeting C‐Reactive Protein in Inflammatory Disease by Preventing Conformational Changes
Thiele, J. R., Zeller, J., Bannasch, H., Stark, G. B., Peter, K., & Eisenhardt, S. U. (2015) · Mediators of Inflammation · doi:10.1155/2015/372432 · Cited by 109
“1,6-bis PC is a derivative of CRP-ligand phosphocholine (PC), and as such it is bound corresponding to phosphocholine in a calciumdependent manner in the PC-binding pocket [106].”
BackgroundC-reactive protein: Risk factor, biomarker and/or therapeutic target?
Genest, J. J. (2010) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(10)71061-8 · Cited by 118
Gold nanoparticles as sensitive optical probes
Yuan, Z., Hu, C.-C., Chang, H., & Lu, C. (2016) · The Analyst · doi:10.1039/c5an02651b · Cited by 106
Mora, S., Musunuru, K., & Blumenthal, R. S. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.109728 · Cited by 102
Metadata
- Authors
- Pepys, M. B., Hirschfield, G. M., Tennent, G. A., Ruth Gallimore, J., Kahan, M. C., Bellotti, V., Hawkins, P. N., Myers, R. M., Smith, M. D., Polara, A., Cobb, A. J. A., Ley, S. V., Andrew Aquilina, J., Robinson, C. V., Sharif, I., Gray, G. A., Sabin, C. A., Jenvey, M. C., Kolstoe, S. E., Thompson, D., & Wood, S. P.
- Affiliations
- The Royal Free Hospital (GB)
- University of Pavia (IT)
- University of Cambridge (GB)
- University of Edinburgh (GB)
- University of Southampton (GB)
- University of Sussex (GB)
- Corresponding author
- Pepys, Mark B.
- ORCID
- Venue
- Nature
- Published
- 2006-04
- Volume
- 440
- Issue
- 7088
- Pages
- 1217-1221
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2080883999
- Cited by
- 672
- References
- 31
- Citations by year
- 2026: 6 · 2025: 17 · 2024: 19 · 2023: 30 · 2022: 27 · 2021: 28 · 2020: 32 · 2019: 21 · 2018: 23 · 2017: 20 · 2016: 23 · 2015: 16 · 2014: 35 · 2013: 30 · 2012: 40
- FWCI
- 26.49
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- CentAUR (University of Reading) (acceptedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- Research Online (University of Wollongong) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Figshare (submittedVersion)
- Funders
- Wellcome Trust
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Biomarkers in Disease Mechanisms
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- C-reactive protein, acute myocardial infarction, complement activation, cardioprotection, infarct size, neuroprotection, cerebral ischemia, small-molecule drug design, acute phase proteins, inflammation, stroke, drug repurposing
- MeSH terms
- Animals, C-Reactive Protein, Cardiovascular Diseases, Complement System Proteins, Hexanes, Humans, Male, Models, Molecular, Molecular Conformation, Myocardial Infarction, Phosphorylcholine, Drug Design, Rats, Wistar, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.